Report copyright - Oryzon Genomics Corporate outlook...Valuation: Risk-adjusted NPV of €328m or €9.6/share We have marginally increased our valuation of Oryzon to €328m or €9.6/share from €322m
Please pass captcha verification before submit form
Please pass captcha verification before submit form